| Primary |
| Thrombosis Prophylaxis |
18.2% |
| Product Used For Unknown Indication |
15.9% |
| Hypertension |
11.4% |
| Acute Myocardial Infarction |
6.8% |
| Prophylaxis |
6.8% |
| Acute Coronary Syndrome |
5.3% |
| Deep Vein Thrombosis |
4.5% |
| Thrombosis |
4.5% |
| Pulmonary Embolism |
3.8% |
| Angina Unstable |
3.0% |
| Coagulopathy |
3.0% |
| Hypertensive Heart Disease |
3.0% |
| Atrial Fibrillation |
2.3% |
| Drug Use For Unknown Indication |
2.3% |
| Anticoagulant Therapy |
1.5% |
| Cerebral Venous Thrombosis |
1.5% |
| Contraception |
1.5% |
| Dvt Prophylaxis |
1.5% |
| Knee Arthroplasty |
1.5% |
| Myocardial Infarction |
1.5% |
|
| Coronary Artery Thrombosis |
12.5% |
| Haematoma |
8.9% |
| Product Quality Issue |
8.9% |
| Spontaneous Haematoma |
8.9% |
| Thrombosis |
8.9% |
| Drug Ineffective |
5.4% |
| Heparin-induced Thrombocytopenia |
5.4% |
| Renal Impairment |
5.4% |
| Vena Cava Thrombosis |
5.4% |
| Catheter Related Complication |
3.6% |
| Haematuria |
3.6% |
| Pain In Extremity |
3.6% |
| Pulmonary Embolism |
3.6% |
| Somnolence |
3.6% |
| Transient Ischaemic Attack |
3.6% |
| Angioedema |
1.8% |
| Atrial Thrombosis |
1.8% |
| Cardiac Failure |
1.8% |
| Cerebral Haemorrhage |
1.8% |
| Condition Aggravated |
1.8% |
|
| Secondary |
| Pulmonary Embolism |
15.8% |
| Drug Use For Unknown Indication |
12.3% |
| Acute Coronary Syndrome |
12.0% |
| Thrombosis Prophylaxis |
8.2% |
| Deep Vein Thrombosis |
7.9% |
| Metastases To Lymph Nodes |
7.0% |
| Trousseau's Syndrome |
7.0% |
| Metastatic Neoplasm |
5.3% |
| Anticoagulant Therapy |
4.7% |
| Product Used For Unknown Indication |
2.6% |
| Vena Cava Thrombosis |
2.6% |
| Thrombosis |
2.3% |
| Acute Myocardial Infarction |
1.8% |
| Adenocarcinoma |
1.8% |
| Breast Cancer Metastatic |
1.8% |
| Renal Vein Thrombosis |
1.8% |
| Pain |
1.5% |
| Antiphospholipid Syndrome |
1.2% |
| Headache |
1.2% |
| Osteoarthritis |
1.2% |
|
| Vena Cava Thrombosis |
7.8% |
| Cerebral Haemorrhage |
5.9% |
| Haemoptysis |
5.9% |
| Ischaemic Stroke |
5.9% |
| Muscular Weakness |
5.9% |
| Pericardial Effusion |
5.9% |
| Pericardial Effusion Malignant |
5.9% |
| Pneumonia |
5.9% |
| Thrombosis |
5.9% |
| Urine Colour Abnormal |
5.9% |
| Deep Vein Thrombosis |
3.9% |
| Dermatomyositis |
3.9% |
| Drug Ineffective |
3.9% |
| Hypertension |
3.9% |
| International Normalised Ratio Increased |
3.9% |
| Lymphadenopathy |
3.9% |
| Shock Haemorrhagic |
3.9% |
| Subdural Haematoma |
3.9% |
| Subdural Haemorrhage |
3.9% |
| Thrombosis In Device |
3.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
14.5% |
| Drug Use For Unknown Indication |
13.7% |
| Non-small Cell Lung Cancer |
10.9% |
| Hypertension |
9.2% |
| Multiple Myeloma |
6.0% |
| Thrombosis Prophylaxis |
5.0% |
| Hiv Infection |
4.8% |
| Coronary Artery Disease |
3.9% |
| Lung Neoplasm Malignant |
3.9% |
| Pain |
3.6% |
| Peripheral T-cell Lymphoma Unspecified |
3.5% |
| Constipation |
3.4% |
| Epilepsy |
2.9% |
| Colorectal Cancer Metastatic |
2.6% |
| Deep Vein Thrombosis |
2.2% |
| Rheumatoid Arthritis |
2.2% |
| Prophylaxis |
2.0% |
| Atrial Fibrillation |
1.9% |
| Nausea |
1.9% |
| Dermatitis |
1.8% |
|
| Thrombocytopenia |
11.9% |
| Weight Decreased |
8.9% |
| Neutropenia |
7.9% |
| Pulmonary Embolism |
7.9% |
| Vomiting |
7.9% |
| Transaminases Increased |
5.9% |
| Arterial Thrombosis Limb |
5.0% |
| Cushing's Syndrome |
5.0% |
| Disease Recurrence |
4.0% |
| Hypoalbuminaemia |
4.0% |
| Thrombosis |
4.0% |
| Thyroid Cancer |
4.0% |
| Cardiac Arrest |
3.0% |
| Drug Interaction |
3.0% |
| Large Intestine Perforation |
3.0% |
| Meningioma |
3.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.0% |
| Pneumonia |
3.0% |
| Sepsis |
3.0% |
| Urinary Tract Infection |
3.0% |
|
| Interacting |
| Acute Myocardial Infarction |
35.7% |
| Mantle Cell Lymphoma |
21.4% |
| Product Used For Unknown Indication |
14.3% |
| Atrial Fibrillation |
7.1% |
| Hypertension |
7.1% |
| Prophylaxis |
7.1% |
| Thrombosis Prophylaxis |
7.1% |
|
| Muscle Haemorrhage |
33.3% |
| Subarachnoid Haemorrhage |
33.3% |
| Tachycardia |
33.3% |
|
